News | Prostate Cancer | October 27, 2016

Augmenix Announces Positive Three-year SpaceOAR Clinical Trial Results

Application of SpaceOAR hydrogel results in lower long-term rectal injury and higher patient quality of life scores

Augmenix, SpaceOAR System, prostate cancer, three-year clinical data results, ASTRO 2016

October 27, 2016 — Augmenix Inc. announced the three-year results from the SpaceOAR System Prostate Cancer US Pivotal Clinical Trial in September at the 2016 annual meeting of the American Society for Radiation Oncology (ASTRO).

The study results, presented by Daniel Hamstra, M.D., Ph.D., a radiation oncologist at Texas Oncology in Irving, Texas, demonstrated significantly lower rectal toxicity and higher patient quality of life (QOL) scores when the SpaceOAR System was applied prior to radiotherapy as compared to the trial control patients.

The leading side effects of prostate cancer radiotherapy are collectively known as “rectal toxicity” (diarrhea, rectal bleeding, urgency, pain, etc.), which results from unintended radiation injury to the rectum (the Organ At Risk, OAR). These complications can last for years, significantly impacting QOL. The SpaceOAR System was developed to push the rectum away from the high dose region during treatment, and then to be completely absorbed by the body after radiotherapy is complete.

The prospective, randomized, multi-center, patient-blinded clinical trial evaluated rectal and urinary toxicity and QOL impact on prostate radiotherapy patients treated either with SpaceOAR hydrogel, or with no hydrogel (controls). Previously published initial study results demonstrated spacer safety, and a significant 74 percent reduction in the volume of rectum receiving 70 Gy radiation at 15 months.

Following radiotherapy through three years, no SpaceOAR patients (0 percent) experienced grade 2 or worse late rectal toxicity, compared to 5.7 percent in the control patients (p=0.012). Additionally, at three years the average SpaceOAR patient bowel QOL was slightly better than before radiotherapy (+0.48 points), while the control patients QOL had significantly declined (-5.3 points, p=0.05). The percent of men with significant 10+ declines in bowel QOL at three years was 20.5 percent and 5.4 percent in the control and SpaceOAR groups (p=0.02), respectively.

Unexpectedly, the SpaceOAR patients also showed benefits in urinary complications and QOL, relative to controls. In the three years after radiotherapy, grade 1 urinary incontinence was experienced in 19.6 percent and 4.3 percent of the control and SpaceOAR patients, respectively (p=0.003). Additionally, like bowel QOL, at three years the average SpaceOAR patient urinary QOL was slightly better than before radiotherapy (+0.6 points), while the control patient QOL had declined (-3.3 points, p=0.05).

“The low level of rectum radiation dose seen in the men who received the spacer in this trial is unprecedented, and it is great to see that the spacer rectum protection is resulting in long-term patient benefits,” said Hamstra. “The idea that three years after treatment patients can be having the same bowel and urinary QOL is wonderful. Essentially patients can complete their treatment and be confident that life can return to normal.”

Using a minimally invasive procedure, the SpaceOAR System is injected as a liquid into the space between the prostate and rectum, where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy, and then liquefies and is completely absorbed.

The SpaceOAR System is U.S. Food and Drug Administration (FDA)-cleared, CE marked and is also approved in Australia and Canada.

For more information: www.augmenix.com

Related Content

FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
Study Assesses Risk of MRI Exams for Patients With Tattoos
News | Magnetic Resonance Imaging (MRI) | February 01, 2019
A new European study concluded that magnetic resonance imaging (MRI) exams pose little risk for people with tattoos,...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...